These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

344 related items for PubMed ID: 35939083

  • 1. The Watts Connectedness Scale: a new scale for measuring a sense of connectedness to self, others, and world.
    Watts R, Kettner H, Geerts D, Gandy S, Kartner L, Mertens L, Timmermann C, Nour MM, Kaelen M, Nutt D, Carhart-Harris R, Roseman L.
    Psychopharmacology (Berl); 2022 Nov; 239(11):3461-3483. PubMed ID: 35939083
    [Abstract] [Full Text] [Related]

  • 2. Emotional breakthrough and psychedelics: Validation of the Emotional Breakthrough Inventory.
    Roseman L, Haijen E, Idialu-Ikato K, Kaelen M, Watts R, Carhart-Harris R.
    J Psychopharmacol; 2019 Sep; 33(9):1076-1087. PubMed ID: 31294673
    [Abstract] [Full Text] [Related]

  • 3. Therapeutic Alliance and Rapport Modulate Responses to Psilocybin Assisted Therapy for Depression.
    Murphy R, Kettner H, Zeifman R, Giribaldi B, Kartner L, Martell J, Read T, Murphy-Beiner A, Baker-Jones M, Nutt D, Erritzoe D, Watts R, Carhart-Harris R.
    Front Pharmacol; 2021 Sep; 12():788155. PubMed ID: 35431912
    [Abstract] [Full Text] [Related]

  • 4. Psychedelic Communitas: Intersubjective Experience During Psychedelic Group Sessions Predicts Enduring Changes in Psychological Wellbeing and Social Connectedness.
    Kettner H, Rosas FE, Timmermann C, Kärtner L, Carhart-Harris RL, Roseman L.
    Front Pharmacol; 2021 Sep; 12():623985. PubMed ID: 33995022
    [Abstract] [Full Text] [Related]

  • 5. Antidepressant effects of a psychedelic experience in a large prospective naturalistic sample.
    Nygart VA, Pommerencke LM, Haijen E, Kettner H, Kaelen M, Mortensen EL, Nutt DJ, Carhart-Harris RL, Erritzoe D.
    J Psychopharmacol; 2022 Aug; 36(8):932-942. PubMed ID: 35924888
    [Abstract] [Full Text] [Related]

  • 6. Trial of Psilocybin versus Escitalopram for Depression.
    Carhart-Harris R, Giribaldi B, Watts R, Baker-Jones M, Murphy-Beiner A, Murphy R, Martell J, Blemings A, Erritzoe D, Nutt DJ.
    N Engl J Med; 2021 Apr 15; 384(15):1402-1411. PubMed ID: 33852780
    [Abstract] [Full Text] [Related]

  • 7. The revival of the psychedelic experience scale: Revealing its extended-mystical, visual, and distressing experiential spectrum with LSD and psilocybin studies.
    Stocker K, Hartmann M, Ley L, Becker AM, Holze F, Liechti ME.
    J Psychopharmacol; 2024 Jan 15; 38(1):80-100. PubMed ID: 37905369
    [Abstract] [Full Text] [Related]

  • 8. Development of the Psychological Insight Questionnaire among a sample of people who have consumed psilocybin or LSD.
    Davis AK, Barrett FS, So S, Gukasyan N, Swift TC, Griffiths RR.
    J Psychopharmacol; 2021 Apr 15; 35(4):437-446. PubMed ID: 33427007
    [Abstract] [Full Text] [Related]

  • 9. Validation of a French Version of the Mystical Experience Questionnaire with Retrospective Reports of the Most Significant Psychedelic Experience among French Users.
    Fauvel B, Kangaslampi S, Strika-Bruneau L, Roméo B, Piolino P.
    J Psychoactive Drugs; 2023 Apr 15; 55(2):170-179. PubMed ID: 35384730
    [Abstract] [Full Text] [Related]

  • 10. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up.
    Carhart-Harris RL, Bolstridge M, Day CMJ, Rucker J, Watts R, Erritzoe DE, Kaelen M, Giribaldi B, Bloomfield M, Pilling S, Rickard JA, Forbes B, Feilding A, Taylor D, Curran HV, Nutt DJ.
    Psychopharmacology (Berl); 2018 Feb 15; 235(2):399-408. PubMed ID: 29119217
    [Abstract] [Full Text] [Related]

  • 11. Psilocybin-assisted therapy for major depressive disorder: An exploratory placebo-controlled, fixed-order trial.
    Sloshower J, Skosnik PD, Safi-Aghdam H, Pathania S, Syed S, Pittman B, D'Souza DC.
    J Psychopharmacol; 2023 Jul 15; 37(7):698-706. PubMed ID: 36938991
    [Abstract] [Full Text] [Related]

  • 12. Psychedelic-assisted psychotherapy for the treatment of major depression: a synthesis of phenomenological explanations.
    Miceli McMillan R, Jordens C.
    Med Health Care Philos; 2022 Jun 15; 25(2):225-237. PubMed ID: 35064398
    [Abstract] [Full Text] [Related]

  • 13. Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial.
    Davis AK, Barrett FS, May DG, Cosimano MP, Sepeda ND, Johnson MW, Finan PH, Griffiths RR.
    JAMA Psychiatry; 2021 May 01; 78(5):481-489. PubMed ID: 33146667
    [Abstract] [Full Text] [Related]

  • 14. Effects of discontinuation of serotonergic antidepressants prior to psilocybin therapy versus escitalopram for major depression.
    Erritzoe D, Barba T, Spriggs MJ, Rosas FE, Nutt DJ, Carhart-Harris R.
    J Psychopharmacol; 2024 May 01; 38(5):458-470. PubMed ID: 38520045
    [Abstract] [Full Text] [Related]

  • 15. Phenomenological assessment of psychedelics induced experiences: Translation and validation of the German Challenging Experience Questionnaire (CEQ) and Ego-Dissolution Inventory (EDI).
    Dworatzyk K, Jansen T, Schmidt TT.
    PLoS One; 2022 May 01; 17(3):e0264927. PubMed ID: 35294453
    [Abstract] [Full Text] [Related]

  • 16. How does psilocybin therapy work? An exploration of experiential avoidance as a putative mechanism of change.
    Zeifman RJ, Wagner AC, Monson CM, Carhart-Harris RL.
    J Affect Disord; 2023 Aug 01; 334():100-112. PubMed ID: 37146908
    [Abstract] [Full Text] [Related]

  • 17. Self-blinding citizen science to explore psychedelic microdosing.
    Szigeti B, Kartner L, Blemings A, Rosas F, Feilding A, Nutt DJ, Carhart-Harris RL, Erritzoe D.
    Elife; 2021 Mar 02; 10():. PubMed ID: 33648632
    [Abstract] [Full Text] [Related]

  • 18. Investigation of self-treatment with lysergic acid diethylamide and psilocybin mushrooms: Findings from the Global Drug Survey 2020.
    Kopra EI, Ferris JA, Winstock AR, Kuypers KP, Young AH, Rucker JJ.
    J Psychopharmacol; 2023 Jul 02; 37(7):733-748. PubMed ID: 36876583
    [Abstract] [Full Text] [Related]

  • 19. Validation of the imperial psychedelic predictor scale.
    Angyus M, Osborn S, Haijen E, Erritzoe D, Peill J, Lyons T, Kettner H, Carhart-Harris R.
    Psychol Med; 2024 Sep 27; 54(12):1-9. PubMed ID: 39327922
    [Abstract] [Full Text] [Related]

  • 20. Psilocybin-assisted therapy improves psycho-social-spiritual well-being in cancer patients.
    Shnayder S, Ameli R, Sinaii N, Berger A, Agrawal M.
    J Affect Disord; 2023 Feb 15; 323():592-597. PubMed ID: 36513161
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.